Clinical trial
Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin…
NCT00471965 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00471965 |
|---|---|
| Title | Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients |
| Official title | Oxaliplatin(Eloxatin®) + 5-FU/LV (FOLFOX4) Compared With Single Agent Doxorubicin (Adriamycin®) as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients Ineligible for Curative Resection or Local Treatment |
| Acronym | EACH |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Hepatocellular |
| Intervention type | Drug |
| Interventions | Oxaliplatin + 5-Fluorouracil/Leucovorin, Doxorubicin |
| Enrollment | 371 |
| Start date | Mar 1, 2007 |
| Primary completion | Mar 1, 2010 |
| Completion | Mar 1, 2010 |
| First posted | May 10, 2007 |
| Last update posted | Sep 20, 2010 |
| Countries | China, South Korea, Taiwan, Thailand |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: